CKDMBD_Guideline指南概要1.ppt

KDIGO Clinical Practice Guideline Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD) An independently incorporated nonprofit foundation, governed by an international board with the stated mission to: ‘Improve the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration, and integration of initiatives to develop and implement clinical practice guidelines.’ KDIGO CKD-MBD Guideline Work Group Members Sharon M. Moe, MD, FASN, FAHA, FACP (Co-chair) United States Geoffrey A. Block, MD United States Jorge B. Cannata-Andía, MD, PhD Spain Grahame J. Elder, MB, BS, PhD, FRACP Australia Masafumi Fukagawa, MD, PhD, FASN Japan Vanda Jorgetti, MD, PhD Brazil Markus Ketteler, MD Germany Craig B. Langman, MD United States Adeera Levin, MD, FRCPC Canada Tilman B. Drüeke, MD, FRCP (Co-chair) France Alison M. MacLeod, MBChB, MD, FRCP United Kingdom Linda McCann, RD, CSR, LD United States Peter A. McCullough, MD, MPH, FACC, FACP, FCCP, FAHA United States Susan M. Ott, MD United States Angela Yee-Moon Wang, MD, PhD, FRCP Hong Kong José R. Weisinger, MD, FACP Venezuela United States David C. Wheeler, MD, FRCP United Kingdom CKD-MBD Guideline Evidence Review Team Tufts Medical Center ERT Katrin Uhlig, MD, MS Project Director; Director, Guideline Development Ranjani Moorthi, MD, MPH, MS Assistant Project Director Amy Earley, BS Project Coordinator Rebecca Persson, BA Research Assistant International Methods Consultant Alison M. MacLeod, MBChB, MD, FRCPUnited Kingdom Guideline Outline Chapter 1: Introduction and Definition of CKD-MBD and the Development of the Guideline Statements Chapter 2: Methodological Approach Chapter 3.1: Diagnosis of CKD-MBD: Biochemical Abnormalities Chapter 3.2: Diagnosis of CKD-MBD: Bone Chapter 3.3: Diagnosis of CKD-MBD: Vascular Calcification Guideline Outline Chapter 4.1: Treatment of CKD-MBD Targeted at Lowe